Future clinical studies will have to address if combined evaluation of E-cadherin protein, COX-2, and pGSK3βS9 could contribute to the identification of patients with metastatic BC who may benefit from combination therapies that target the PGE2 signaling pathway. The gene discussed is CDH1; the disease is breast cancer.